Joint Filing AgreementJoint Filing Agreement • September 7th, 2005 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of Idenix Pharmaceuticals, Inc., a Delaware corporation. Date: September 2, 2005
June 11, 2004Lock-Up Agreement • August 6th, 2004 • Novartis Bioventures LTD • Pharmaceutical preparations
The undersigned understands that you, as representatives (the "Representatives"), propose to enter into an Underwriting Agreement on behalf of the several Underwriters named in Schedule I to such agreement (collectively, the "Underwriters"), with Idenix Pharmaceuticals, Inc., a Delaware corporation (referred to herein as the "Company"), providing for a public offering (the "Offering") of common stock of the Company (the "Shares") pursuant to a Registration Statement on Form S-1 (the "Registration Statement") to be filed with the Securities and Exchange Commission (the "SEC").
JOINT FILING AGREEMENTJoint Filing Agreement • August 6th, 2004 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of Idenix Pharmaceuticals, Inc., a Delaware corporation.
as Representatives of the several Underwriters to be named in the within- mentioned Underwriting AgreementUnderwriting Agreement • July 6th, 2017 • Novartis Bioventures LTD • Pharmaceutical preparations
Joint Filing AgreementJoint Filing Agreement • April 5th, 2019 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Novus Therapeutics, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.
Joint Filing AgreementJoint Filing Agreement • February 11th, 2022 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
ESCROW AGREEMENTEscrow Agreement • August 3rd, 2010 • Novartis Bioventures LTD • Pharmaceutical preparations • Delaware
THIS ESCROW AGREEMENT, dated as of July 21, 2010 (this “Agreement”), is by and among MDRNA, Inc., a Delaware corporation (“Purchaser”), Ampersand 2006 Limited Partnership, solely in its capacity as representative of the stockholders of Cequent Pharmaceuticals, Inc. pursuant to the Merger Agreement (as defined below) (the “Stockholder Representative”), and American Stock Transfer and Trust Company, LLC (the “Escrow Agent”). Each capitalized term used in this Agreement but not otherwise defined herein shall have the meaning ascribed thereto in the Merger Agreement. Purchaser shall provide the Escrow Agent with a true and complete copy of the Merger Agreement for its records and reference.
Joint Filing AgreementJoint Filing Agreement • April 16th, 2020 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Aileron Therapeutics, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.
JOINT FILING AGREEMENTJoint Filing Agreement • April 10th, 2017 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13G with respect to the Common Shares beneficially owned by each of them of Merus N.V. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13G.
Joint Filing AgreementJoint Filing Agreement • February 5th, 2019 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing AgreementJoint Filing Agreement • May 15th, 2018 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing AgreementJoint Filing Agreement • October 1st, 2014 • Novartis Bioventures LTD • Pharmaceutical preparations
Each of the undersigned hereby expresses its agreement that the attached Schedule 13D (and any amendments thereto) relating to the Common Stock of Tokai Pharmaceuticals, Inc. is filed on behalf of each of the undersigned.
Joint Filing AgreementJoint Filing Agreement • June 7th, 2019 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Aerpio Pharmaceuticals, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.
Joint Filing AgreementJoint Filing Agreement • April 22nd, 2020 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Aerpio Pharmaceuticals, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.
Joint Filing AgreementJoint Filing Agreement • April 13th, 2020 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Aileron Therapeutics, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.
Joint Filing AgreementJoint Filing Agreement • February 25th, 2016 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing AgreementJoint Filing Agreement • January 29th, 2021 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing AgreementJoint Filing Agreement • February 1st, 2021 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing AgreementJoint Filing Agreement • March 27th, 2017 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing AgreementJoint Filing Agreement • February 2nd, 2018 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
JOINT FILING AGREEMENT OF NOVARTIS BIOVENTURES LTD. AND NOVARTIS AGJoint Filing Agreement • January 26th, 2011 • Novartis Bioventures LTD • Pharmaceutical preparations
The undersigned persons agree and consent pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, as of the date set forth below, to the joint filing on their behalf of the Amendment to Schedule 13D to which this Exhibit is attached, in connection with their beneficial ownership of the common stock of Marina Biotech, Inc. at January 25, 2011 and agree that such statement is filed on behalf of each of them.
Joint Filing AgreementJoint Filing Agreement • April 14th, 2016 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
June 11, 2004Lock-Up Agreement • August 6th, 2004 • Novartis Bioventures LTD • Pharmaceutical preparations
The undersigned understands that you, as representatives (the "Representatives"), propose to enter into an Underwriting Agreement on behalf of the several Underwriters named in Schedule I to such agreement (collectively, the "Underwriters"), with Idenix Pharmaceuticals, Inc., a Delaware corporation (referred to herein as the "Company"), providing for a public offering (the "Offering") of common stock of the Company (the "Shares") pursuant to a Registration Statement on Form S-1 (the "Registration Statement") to be filed with the Securities and Exchange Commission (the "SEC").
Joint Filing AgreementJoint Filing Agreement • April 29th, 2019 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Aerpio Pharmaceuticals, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.
Joint Filing AgreementJoint Filing Agreement • May 16th, 2017 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Tokai Pharmaceuticals, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.
Joint Filing AgreementJoint Filing Agreement • October 4th, 2018 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing AgreementJoint Filing Agreement • August 23rd, 2017 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Altimmune, Inc. (f/k/a PharmAthene, Inc.). The undersigned hereby further agree that this Joint Filing Agreement be included as an exhibit to any such statement and any such amendment. The undersigned further agree that each party hereto is responsible for the timely filing of such statements and amendments, and for the completeness and accuracy of the information concerning it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning any other filing party, unless such party knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed s
Joint Filing AgreementJoint Filing Agreement • February 1st, 2021 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
JOINT FILING AGREEMENTJoint Filing Agreement • June 3rd, 2016 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13G with respect to the Common Shares beneficially owned by each of them of Merus N.V. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13G.
Joint Filing AgreementJoint Filing Agreement • March 18th, 2019 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Aileron Therapeutics, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.
JOINT FILING AGREEMENTJoint Filing Agreement • February 2nd, 2018 • Novartis Bioventures LTD • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing AgreementJoint Filing Agreement • January 7th, 2016 • Novartis Bioventures LTD • Biological products, (no disgnostic substances)
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing AgreementJoint Filing Agreement • February 1st, 2021 • Novartis Bioventures LTD • Biological products, (no disgnostic substances)
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing AgreementJoint Filing Agreement • April 17th, 2018 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Novus Therapeutics, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.
Joint Filing AgreementJoint Filing Agreement • July 6th, 2017 • Novartis Bioventures LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Aileron Therapeutics, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.
